IMMUNABS
ImmunAbs Inc. (www.immunabs.com ) announced that it has received US FDA approval for a Phase 1 clinical trial and that it is now ready to initiate a phase 1 clinical trial in the United States.
ImmunAbs is developing IM-101, a monoclonal antibody targeting complements that play essential roles in the immune system but, when out of regulation, cause various autoimmune diseases, including but not limited to paroxysmal nocturnal hemoglobinuria (PNH). The complement inhibitors drug market showed its growth potential by achieving an average annual growth rate of 20.7% and a market size of USD $ 5.1 billion in 2020 and is expected to grow to USD $19 billion by 2027.
Paroxysmal nocturnal hemoglobinuria is one example of complement-mediated autoimmune diseases where the membrane proteins protecting the red blood cells from complement activation are lost due to mutations, which results in red blood cells being destructed by the complements. Due to insufficient inhibition of complements shown by currently approved complement inhibitors, SolirisⓇ and UltomirisⓇ , patients who receive these drugs still suffer from the residual symptoms of PNH, which include anaemia, fatigue, and decreased productivity at work.
ImmunAbs’ new complement therapeutic IM-101 targets the safest and most potent component of the complement system, complement C5. IM-101 has been shown to completely inhibit complement activation, and thus is expected to alleviate the symptoms that persist with the standard of care. ImmunAbs will initiate a phase 2a clinical trial in the United States in 2024.
“This is a historical milestone for ImmunAbs.” said Dr. DongJo Kim, the company’s CEO. “We are delighted to see IM-101’s efficacy in humans which has been proven in our ex vivo study. We hope that our IM-101 will reach patients who may suffer from symptoms that persist due to insufficient complement inhibition by the current treatments.”
About ImmunAbs Inc.
ImmunAbs Inc. was established in 2017 by experts of global standard antibody therapeutics development. The vision is "Hope for Patients, Dreams for All." Currently, ImmunAbs has several antibody therapeutics in global standard development for autoimmune diseases, diabetic retinopathy, and metabolic syndrome. ImmunAbs successfully raised KRW 18.1 billion from Seed to series A funding in 2021 and got a non-clinical study national grant for developing IM-101 from Korea Drug Development Fund in November last year.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220803005380/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Thales Named Frost & Sullivan’s 2025 Company of the Year in Automated Border Control24.10.2025 08:00:00 CEST | Press release
Thales, a global leader in cybersecurity and identity management, has been recognized by Frost & Sullivan as Company of the Year 2025 in the Automated Border Control (ABC) eGates industry.This award underscores Thales’s ability to consistently innovate, deliver scalable and sustainable solutions, and set new standards for border security and passenger experience worldwide.Frost & Sullivan emphasized Thales’s proven ability to deliver at scale, its close collaboration with ministries of interior and airport operators, and its forward-looking strategy that integrates regulatory compliance, digital identity, and sustainability. As governments and airports face rising passenger volumes, new regulatory requirements such as the European Entry Exit System (EES), and evolving security threats, Thales’s solutions help strike the right balance between strong security and traveller convenience. Frost & Sullivan praised Thales’s end-to-end expertise, customer focus, and ability to design systems t
NTT DOCOMO BUSINESS and NTT Com Asia Launch “APN InterLink” Service in Hong Kong24.10.2025 06:00:00 CEST | Press release
Transforming the Financial Services Industry with IOWN® Infrastructure NTT DOCOMO BUSINESS, Inc. (formerly NTT Communications Corporation, hereafter “NTT DOCOMO BUSINESS”) and its Hong Kong subsidiary, NTT Com Asia, today announced the launch of the “APN InterLink” service in Hong Kong for financial institutions starting November 1, 2025, leveraging All-Photonic Network (APN)*1 technology in support of the IOWN®*2 initiative. Commercially deployed in Hong Kong, one of the leading Asia financial hubs, the new service leverages ultra-low latency photonics-based connectivity to address the evolving digital needs of the financial sector, especially for latency-sensitive trading, algorithmic trading*3, proximity market data access and real-time transaction. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251023916941/en/ NTT APN InterLink Service Looking ahead, NTT DOCOMO BUSINESS and NTT Com Asia plan to expand the deployment of
Hanshow Wins the Technology Vendor of the Year at 2025 RTIH Innovation Awards in London24.10.2025 05:00:00 CEST | Press release
Hanshow, a global leader in digital retail solutions, has been honoured at the 2025 Retail Technology Innovation Hub (RTIH) Innovation Awards, winning the Technology Vendor of the Year title for its pioneering shelf marketing solution. The recognition underscores Hanshow’s commitment to redefining how retailers and brands engage with shoppers through NFC-enabled ESLs that seamlessly connect physical stores with digital engagement. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251023122859/en/ The RTIH Innovation Awards are widely regarded as one of the most influential recognitions in the global retail technology sector. Each year, the awards celebrate organisations driving innovation, digital transformation, and operational excellence in a fast-moving omnichannel world. The 2025 ceremony, held at The HAC in central London, brought together senior retail executives, technology innovators, and thought leaders shaping the fut
DNIB.com Reports Internet Has 378.5 Million Domain Name Registrations at the End of the Third Quarter of 202523.10.2025 23:00:00 CEST | Press release
VeriSign, Inc. (NASDAQ: VRSN), a global provider of critical internet infrastructure and domain name registry services, today announced that, according to the latest Domain Name Industry Brief Quarterly Report from DNIB.com, the third quarter of 2025 closed with 378.5 million domain name registrations across all top-level domains (TLDs), an increase of 6.8 million domain name registrations, or 1.8% compared to the second quarter of 2025. Domain name registrations also increased by 16.2 million, or 4.5%, year over year. The .com and .net TLDs had a combined total of 171.9 million domain name registrations in the domain name base at the end of third quarter of 2025, an increase of 1.4 million domain name registrations, or 0.8% compared to the second quarter of 2025. The .com and .net TLDs had a combined increase of 2.4 million domain name registrations, or 1.4%, year over year. As of Sept. 30, 2025, the .com domain name base totaled 159.4 million domain name registrations and the .net do
Copeland Expands Industrial Heat Pump Portfolio with Agreement to Acquire SPH Sustainable Process Heat23.10.2025 22:30:00 CEST | Press release
Acquisition enhances Copeland’s industrial heating portfolio Copeland, a global leader in sustainable climate solutions, today announced its agreement to acquire SPH Sustainable Process Heat (SPH), a Germany-based industrial heat pump technology company. This acquisition is expected to expand Copeland’s industrial heating portfolio, allowing the company to deliver a broader range of key heat pump technologies and solutions to new and existing customers. Copeland’s industrial business operates under the brand name Vilter. SPH will continue to operate independently until closing. This acquisition reinforces Copeland’s commitment to enabling the energy transition, in this case, through innovative technologies that enable industrial customers to replace fossil-fuel systems with more energy-efficient heating alternatives. SPH brings a strong technology portfolio, including its innovative ThermBooster™ technology, and demonstrated capability in delivering solutions to a broad range of indust
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom